Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Watkins

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|August 1, 1990
The erythromycin breath test as a predictor of cyclosporine blood levelsP B Watkins, T A Hamilton, T M Annesley, et al.
Hepatology (Baltimore, Md.)|June 1, 1996
The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicityR J Fontana, D K Turgeon, T F Woolf, et al.
The Journal of Clinical Investigation|February 1, 1989
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patientsP B Watkins, S A Murray, L G Winkelman, et al.
Clinical Pharmacology and Therapeutics|November 1, 1992
Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipientsD K Turgeon, D P Normolle, A B Leichtman, et al.
Molecular Pharmacology|May 1, 1997
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3P Schmiedlin-Ren, K E Thummel, J M Fisher, et al.
Pharmaceutical Research|December 16, 2014
MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and BioenergeticsY Yang, S Nadanaciva, Y Will, et al.
Canadian Journal of Physiology and Pharmacology|March 1, 1995
Pharmacogenetics in clinical pharmacology and toxicologyT Inaba, D W Nebert, B Burchell, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 7, 2014
A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trialB A Howell, S Q Siler, L K M Shoda, et al.
Drug Metabolism Reviews|January 4, 2001
The human CYP3A subfamily: practical considerationsS A Wrighton, E G Schuetz, K E Thummel, et al.
The Journal of Clinical Investigation|October 1, 1987
Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated ratsS A Wrighton, P E Thomas, P Willis, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|August 1, 1990
The erythromycin breath test as a predictor of cyclosporine blood levelsP B Watkins, T A Hamilton, T M Annesley, et al.
Hepatology (Baltimore, Md.)|June 1, 1996
The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicityR J Fontana, D K Turgeon, T F Woolf, et al.
The Journal of Clinical Investigation|February 1, 1989
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patientsP B Watkins, S A Murray, L G Winkelman, et al.
Clinical Pharmacology and Therapeutics|November 1, 1992
Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipientsD K Turgeon, D P Normolle, A B Leichtman, et al.
Molecular Pharmacology|May 1, 1997
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3P Schmiedlin-Ren, K E Thummel, J M Fisher, et al.
Pharmaceutical Research|December 16, 2014
MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and BioenergeticsY Yang, S Nadanaciva, Y Will, et al.
Canadian Journal of Physiology and Pharmacology|March 1, 1995
Pharmacogenetics in clinical pharmacology and toxicologyT Inaba, D W Nebert, B Burchell, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 7, 2014
A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trialB A Howell, S Q Siler, L K M Shoda, et al.
Drug Metabolism Reviews|January 4, 2001
The human CYP3A subfamily: practical considerationsS A Wrighton, E G Schuetz, K E Thummel, et al.
The Journal of Clinical Investigation|October 1, 1987
Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated ratsS A Wrighton, P E Thomas, P Willis, et al.
Pageof 10